ÂÜÀòÂÒÂ×

Dr. Kevin Healy is Enzyvant’s Senior Vice President, Quality and Compliance. In this role, Dr. Healy serves as the Chief Compliance Officer and leads Enzyvant’s Compliance and Quality departments. He is responsible for oversight of quality systems at Enzyvant and its partner organizations. Dr. Healy has had multiple leadership positions at Enzyvant, including responsibility for Pharmacovigilance and Regulatory Affairs. His leadership of the Regulatory Affairs department included guiding RETHYMIC® to an FDA approval in 2021.

Dr. Healy brings over 15 years of biotech and pharmaceutical experience to his role at Enzyvant. He was previously the head of Global Regulatory Affairs at Roivant Sciences and led development and successful filings for several therapies in the autoimmune and rare disease portfolio at Mallinckrodt Pharmaceuticals. He also served on global development teams for hepatitis B and C virus treatments at Gilead Sciences.

Dr. Healy received his Bachelor of Science in Biological Sciences from Cornell University, his Ph.D. in Biochemistry from the University of Wisconsin–Madison and completed a postdoctoral research fellowship at the University of North Carolina at Chapel Hill.